[Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose].
We report the positive results of two large prospective studies of pharmacological prevention of type 2 diabetes presented at the EASD Congress in Glasgow, September 12, 2001. In the "Diabetes Prevention Program", metformin (2 x 850 mg/day), a biguanide compound, reduces the progression from impaired glucose tolerance towards type 2 diabetes by 31% (p < 0.001) while in the "STOP-NIDDM trial", acarbose (3 x 100 mg/day), an alpha-glucosidase inhibitor, diminished it by 24% (p < 0.002). These results are, however, less marked than those obtained with lifestyle modifications including better dietary habits and increased physical exercise (-58% versus control group, p < 0.001).
Scheen
A J
AJ
Service de Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine, Université de Liège.
D020909:Acarbose / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology / Q000517:prevention & control*; D004032:Diet; D018450:Disease Progression; D015444:Exercise; D005260:Female; D018149:Glucose Intolerance / Q000150:complications* / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D008687:Metformin / Q000494:pharmacology*; D008875:Middle Aged; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
D007004:Hypoglycemic Agents; D008687:Metformin; D020909:Acarbose
Info-congrès. Prévention pharmacologique de la progression de la diminution de la tolérance au glucose vers le diabète de type 2: effets favorables de la metformine et de l'acarbose.